BLFS

BioLife Solutions (BLFS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

Insider Trades

BioLife CEO De Greef's Entire Reported Stake Is Gone, But Repligen's Merger Closing Did It, Not Open-Market Sales

A filing shows performance shares vested at about 200% before the merger closed, then the CEO's holdings were withheld or converted.

Markets

Repligen Closes BioLife Deal: 0.1442 Shares Plus $11.25 Cash Per Share, And Every Director Is Gone

BioLife is now a Repligen subsidiary after a Monday stockholder vote, and plans to deregister from the SEC.